BYDUREON 2 mg, powder and solvent for injectable suspension with extended release in a pre-filled pen 4 pens
Active ingredients: Exenatide
Commercialized according to BDPMDispensing in France: Prescription only
Powder and solvent for injectable suspension with extended release4 penssous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- BYDUREON 2 mg, poudre et solvant pour suspension injectable à libération prolongée en stylo prérempli
- Pharmaceutical form
- poudre et solvant pour suspension injectable à libération prolongée
- Route of administration
- sous-cutanée
- Presentation description
- 4 stylo prérempli en verre avec aiguille(s)
- Marketing authorisation holder
- ASTRAZENECA AB
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 30 Sept 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66105532CIP72801201CIP133400928012012Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| EXÉNATIDEpoudre | 2 mg · un stylo prérempli | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.